Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABADDLF 80 Equity-to-Asset is 0.43 as of Jun. 2026, which is 5% above its 10-year median of 0.41. GuruFocus rates ADDLF with a GF Score™ of 80/100 and a GF Value™ of $14.61. The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, AddLife AB ranks worse than 73.54% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AddLife AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $598 Mil. AddLife AB's Total Assets for the quarter that ended in Jun. 2026 was $1,388 Mil.
Therefore, AddLife AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.43.
The historical rank and industry rank for AddLife AB's Equity-to-Asset or its related term are showing as below:
ADDLF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.41 Max: 0.52
Current: 0.43
During the past 13 years, the highest Equity to Asset Ratio of AddLife AB was 0.52. The lowest was 0.35. And the median was 0.41.
ADDLF's Equity-to-Asset is ranked worse than 73.54% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ADDLF: 0.43
AddLife AB (OTCPK:ADDLF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AddLife AB Equity-to-Asset Related Terms
AddLife AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for AddLife AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADDLF vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, AddLife AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AddLife AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AddLife AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB (ADDLF) has a Equity-to-Asset of 0.43 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AddLife AB and its competitors. This is near median its historical median of 0.41. Over the past decade, AddLife AB's Equity-to-Asset has ranged from 0.35 to 0.52. According to the industry distribution chart, AddLife AB ranks #628 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 73.5%.
Is AddLife AB's Equity-to-Asset too high?
AddLife AB's current Equity-to-Asset of 0.43 is near median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.52. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. AddLife AB's value of 0.43 is 32.8% below this industry median. Based on the distribution chart, AddLife AB ranks #628 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AddLife AB has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #628 out of 854 companies for Equity-to-Asset. This places AddLife AB in the lower half of its industry. The industry median Equity-to-Asset is 0.64. AddLife AB's value of 0.43 is 32.8% below this benchmark. Historically, AddLife AB's own Equity-to-Asset has ranged from 0.35 to 0.52 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 0.64, AddLife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current Equity-to-Asset of 0.43 is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AddLife AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current Equity-to-Asset is 0.43, which is near median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
AddLife AB (ADDLF) has a current Equity-to-Asset of 0.43. The stock's GF Value™ is $14.61, compared to a current price of $15.75 — trading 7.8% above its estimated fair value. The current Equity-to-Asset is 0.43, which is near median its 10-year median of 0.41 and 32.8% below the Medical Devices & Instruments industry median of 0.64. AddLife AB's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AddLife AB (ADDLF), the current Equity-to-Asset is 0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (ADDLF) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of $15.75 is trading 7.8% above its estimated GF Value™ of $14.61.
Key valuation signals for ADDLF:
Equity-to-Asset: 0.43 (near median its 10-year median of 0.41)
GF Value™: $14.61 vs. price of $15.75 (7.8% above fair value)
Industry Position: 32.8% below the Medical Devices & Instruments median (#628 of 854)
No single metric tells the full story. See the ADDLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
80GF Score
Get the complete analysis for ADDLF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADDLF has been successfully added to your 
